ShangPharma, the pre-clinical CRO based in Shanghai, attained the first milestone in its strategic partnership with Jiangsu Hengrui Medicine Co. The partnership, which was announced just four months ago in September 2011, is developing novel therapeutic monoclonal antibodies for an unspecified disease area. More details.... Stock Symbol: (NYSE: SHP) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});